Affordable Access

[Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].

Authors
  • Kobayashi, Shigeto
  • Kanai, Yoshinori
Type
Published Article
Journal
Nihon rinsho. Japanese journal of clinical medicine
Publication Date
Dec 01, 2002
Volume
60
Issue
12
Pages
2351–2356
Identifiers
PMID: 12510361
Source
Medline
License
Unknown

Abstract

The early suppression of disease activity during the first 2 years in rheumatoid arthritis (RA) has been reported to be exclusively important to prevent joint destruction and functional decline. Since single disease-modifying antirheumatic drugs(DMARDs) therapy is still disappointing, many rheumatologists today advocated a more aggressive approach using combinations of classic DMARDs. Many clinical trials on combination therapy have been reported and most studies of combination therapy focused on the efficacy of a treatment strategy. Therefore, the possible synergistic action of combination of drugs has not been demonstrated. Among combination of therapy of classical DMARDs, only few trials demonstrated the efficacy of combination therapy. The incidence of adverse effects among 341 RA patients was investigated by our department. The incidence of adverse effect in combination therapy revealed 36.4% which was not statistically different from that in monotherapy(33.6%, p = 0.41). The recent studies on combination therapy on classical DMARDs are not encouraging, however, the combination therapy for patients with early RA, drugs utilizing immunosuppressant, biologics and other newly developed drugs will still have a chance to expect a potent efficacy for RA.

Report this publication

Statistics

Seen <100 times